Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 79

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Multiple sclerosis+1

Not recruiting

Phase 1 study of remibrutinib exposure in cerebrospinal fluid after oral dosing in healthy participants

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Autoimmune disorder

Not recruiting

Safety and Pharmacokinetics of Oral PTC844 in Healthy Participants for Autoimmune Disorder Treatment

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Sponsor:PTC Therapeutics Inc.

Dermatitis atopic

Not recruiting

A study testing TRIV-509 compared to placebo in adults with moderate to severe atopic dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:HUMAN IGG1 BISPECIFIC MONOCLONAL ANTIBODY AGAINST KALLIKREIN-5 AND KALLIKREIN-7
  • Sponsor:Triveni Bio Inc.

Conjunctivitis allergic

Not recruiting

Study of bilastine for effectiveness, safety and quality of life in children aged 6 to 12 years with allergic rhinoconjunctivitis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bilastine
  • Sponsor:A. Menarini Industrie Farmaceutiche Riunite S.r.l.

Warm autoimmune haemolytic anaemia+1

Not recruiting

Study of ianalumab for adults with primary immune thrombocytopenia or warm-antibody autoimmune hemolytic anemia who previously responded to ianalumab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Danazol
  • Sponsor:Novartis Pharma AG

Multiple sclerosis

Not recruiting

A Study Comparing Two Forms of Ocrelizumab Given Under the Skin in Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Immunodeficiency common variable

Not recruiting

A Study of Leniolisib Safety and Effectiveness for Immune System Problems in Patients with Common Variable Immunodeficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Leniolisib Phosphate
  • Sponsor:Pharming Technologies B.V.

Colitis ulcerative+4

Not recruiting

A study comparing how ritlecitinib capsules work when sprinkled on food versus swallowed whole and with or without food in healthy adults

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Sponsor:Pfizer Inc.

Crohn's disease

Not recruiting

A study using the radiotracer vercirnon to examine its distribution in the body of healthy participants for research on Crohn's disease

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · Healthy volunteers
  • Substances:VERCIRNON
  • Sponsor:AstraZeneca AB

Dermatomyositis

Not recruiting

A study testing brepocitinib compared to placebo for adults with dermatomyositis to see if it works and is safe

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Brepocitinib Tosilate
  • Sponsor:Priovant Therapeutics Inc.

Vitiligo

Not recruiting

Testing delgocitinib cream for patients with vitiligo on the face

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Sponsor:Gentofte Hospital

Dermatitis atopic

Not recruiting

A Study of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis Who Did Not Respond Well Enough to Dupilumab Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dupilumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.